Search results
Author(s):
Ahmad Masri
Added:
9 months ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34…
View more
Christopher Maroules
Job title: Cardiac radiologist, Director of Cardiac Imaging (SimonMed), Co-Founder and COO (Innovation Health Services)
Author
New Horizons in Cardiomyopathy 2026
Video Series
Suneet Mittal
Research Area(s) / Expertise:
Job title: Director of the Electrophysiology Laboratory
Author
Pharmacological Therapy of HFrEF in 2025
Author(s):
Massimo Mapelli
,
Filippo Maria Rubbo
,
Simona Costantino
,
et al
Added:
11 months ago
Review Article
Author(s):
John JV McMurray
Added:
1 year ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home…
View more
Author(s):
Michelle Kittleson
Added:
1 year ago
ESC 2024 - We are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE HF2Recorded remotely from Los Angeles, 2024.Editors: Jordan Rance and Mirjam Boros.Videographers: Mike Knight, Dan Brent,…
View more
Author(s):
Akshay S Desai
Added:
1 year ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3…
View more
Author(s):
Michelle Kittleson
Added:
10 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial…
View more
Author(s):
Michelle Kittleson
Added:
12 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific…
View more